Blog

Paul Sargos: TMT and concomitant Chemo regimen for patients with Muscle Invasive Bladder Cancer

Paul Sargos/X

Nov 25, 2024, 17:19

Paul Sargos: TMT and concomitant Chemo regimen for patients with Muscle Invasive Bladder Cancer

Paul Sargos, Head of the Radiology Department at Bergonie Institute, shared a post X about recent paper by him as co-author, titled “Concomitant Chemotherapy in Trimodal Treatment of Patients with Muscle Invasive Bladder Cancer: A Systematic Review of Prospective Trials” published on Science Direct.

Authors: Camille Baudelin, Paul Sargos, Derek Dinart, Christophe Hennequin, Diego Teyssonneau, Lucie Meynard, Nam-Son Vuong, Félix Lefort, Michael Baboudjian, Guilhem Roubaud.

“Our systematic review focusing on TMT and concomitant Chemo regimen for patients with MIBC

Heterogeneity ++
Overall, similar OS and safety outcomes
Highest LOE=5FU-Mitomycin C
Data regarding elderly patients and QOL insufficiently reported.”

Camille Baudelin cancer Christophe Hennequin Derek Dinart Diego Teyssonneau Félix Lefort Guilhem Roubaud Lucie Meynard Michael Baboudjian muscle invasive bladder cancer Nam-Son Vuong OncoDaily Oncology Paul Sargos Science Direct

Leukemia: Symptoms, Causes, Types, Diagnosis & Treatment

U.S. FDA Approval of Ziihera for the Previously Treated, Unresectable or IHC 3+ Biliary Tract Cancer

ASCO GI 2025 - Everything You Need To Know About Biggest Gastrointestinal cancer Symposium

Side Effects of Radiotherapy: Risks and What to Know

Isabel Rubio has been elected as the President of the European Cancer Organisation for 2026-2027

Special Coverage